Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079282 · ClinicalTrials.gov registry record · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
A Phase 1 study of Relapsed or Refractory T Cell Lymphoma, sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT05079282: Recruiting Phase 1 study of Relapsed or Refractory T Cell Lymphoma, sponsored by Ono Pharmaceutical Co..
NCT05079282 is a Phase 1 study of Relapsed or Refractory T Cell Lymphoma that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 217 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (262% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05079282, a Phase 1 study of Relapsed or Refractory T Cell Lymphoma, is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Primary Outcome
Adverse events with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 used as a guide for the grading of severity.
Conditions Studied
Interventions
- DRUG ONO-4685
Study Locations (20)
California
- City of Hope - Duarte
- University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center - Orange
- Stanford Cancer Institute - Palo Alto
New York
- Roswell Park Cancer Institute - Buffalo
- New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- UT Southwestern Medical Center - Dallas
- MD Anderson - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 1 |
What NCT05079282 shows while recruiting
NCT05079282 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (262% higher).
The record links to 1 condition, with Relapsed or Refractory T Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ONO-4685 is the first listed.
NCT05079282 names 20 study sites across 15 states, led by California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05079282 about?
NCT05079282 is a clinical study titled "Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma". This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
What is the current status of trial NCT05079282?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2021-12-10. Estimated completion is 2028-08-31.
What conditions does trial NCT05079282 study?
This clinical trial studies the following conditions: Relapsed or Refractory T Cell Lymphoma.
What interventions are being tested in trial NCT05079282?
The interventions under investigation include: ONO-4685 (DRUG).
Who is sponsoring clinical trial NCT05079282?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05079282 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05079282's enrollment target sits among peer trials
217 241st of 2000 higher than 1,758 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI